2024 Investorideas.com report predicts 18% CAGR for pancreatic cancer market, reaching $36bn by 2036, with Oncolytics Biotech® Inc.
2024 report by Investorideas.com highlights pancreatic cancer market growth, driven by a CAGR of ~18% from 2024-2036 and a revenue of USD 36bn by 2036 (up from USD 6bn in 2023). Oncolytics Biotech® Inc., a clinical-stage immunotherapeutics company focusing on oncology, is among the featured companies in this sector. The American Cancer Society projects 66,440 pancreatic cancer diagnoses in the US in 2024.
March 06, 2024
3 Articles